Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Castration-resistant Prostate Cancer, MCRPC”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT03658447
What this trial is testing

PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
Peter MacCallum Cancer Centre, Australia 37
Not applicableLooking for participantsNCT07093801
What this trial is testing

Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
Novartis Pharmaceuticals 300
Large-scale testing (Phase 3)Study completedNCT03016312
What this trial is testing

Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Hoffmann-La Roche 759
Testing effectiveness (Phase 2)Ended earlyNCT04458311
What this trial is testing

Abiraterone Acetate in Combination With Tildrakizumab

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
Institute of Cancer Research, United Kingdom 13
Testing effectiveness (Phase 2)Study completedNCT05670106
What this trial is testing

Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 62
Early research (Phase 1)Looking for participantsNCT07537010
What this trial is testing

3D1015 Injection for Patients With mCRPC

Who this might be right for
Metastatic Castration-resistant Prostate Cancer, mCRPC
Chunjing Yu 8
Not applicableStudy completedNCT02426333
What this trial is testing

Optimizing Abiraterone Therapy

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
Radboud University Medical Center 56
Not applicableLooking for participantsNCT06141993
What this trial is testing

ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials

Who this might be right for
Prostate CancerProstate AdenocarcinomaProstate Cancer Metastatic+1 more
Duke University 120
Not applicableStudy completedNCT06809426
What this trial is testing

Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate Cancer

Who this might be right for
PSMA PET-Positive Castration-Resistant Prostate Cancer
Affiliated Hospital of Jiangnan University 13
Not applicableUnknownNCT04833517
What this trial is testing

Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study)

Who this might be right for
Prostate Cancer MetastaticCastration Resistant Prostatic CancerAdvanced Prostate Carcinoma
Universität des Saarlandes 500
Large-scale testing (Phase 3)Study completedNCT02987543
What this trial is testing

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
AstraZeneca 387
Testing effectiveness (Phase 2)Study completedNCT03179410
What this trial is testing

PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer

Who this might be right for
Prostate Cancer
Andrew J. Armstrong, MD 15
Large-scale testing (Phase 3)Looking for participantsNCT06136650
What this trial is testing

Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC 1,314
Testing effectiveness (Phase 2)Study completedNCT01360840
What this trial is testing

EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer

Who this might be right for
Prostate Cancer Metastatic
EMD Serono 180
Testing effectiveness (Phase 2)Active Not RecruitingNCT07285694
What this trial is testing

AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Arsenal Biosciences, Inc. 190
Large-scale testing (Phase 3)Active Not RecruitingNCT02194842
What this trial is testing

Phase III Radium 223 mCRPC-PEACE III

Who this might be right for
Prostate Cancer
European Organisation for Research and Treatment of Cancer - EORTC 446
Early research (Phase 1)Looking for participantsNCT06784193
What this trial is testing

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)+3 more
Olema Pharmaceuticals, Inc. 180
Post-approval studies (Phase 4)Looking for participantsNCT06706921
What this trial is testing

18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer

Who this might be right for
Prostatic NeoplasmsProstatic Neoplasms, Castration-ResistantMetastatic Prostate Cancer+8 more
VA Greater Los Angeles Healthcare System 15
Large-scale testing (Phase 3)Active Not RecruitingNCT03574571
What this trial is testing

Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Who this might be right for
Prostate Cancer
Memorial Sloan Kettering Cancer Center 732
Not applicableWithdrawnNCT04742972
What this trial is testing

Prostate PMSABR Study

Who this might be right for
Prostate Cancer
Darren Poon
Next Page